TD Cowen Maintained a Hold Rating on Myriad Genetics (MYGN)

Myriad Genetics, Inc. (NASDAQ:MYGN) is one of the Best 52-Week Low Penny Stocks to Buy Now. On August 5, Daniel Brennan from TD Cowen maintained a Hold rating on Myriad Genetics, Inc. (NASDAQ:MYGN) with a $6 price target.

The rating follows the company’s fiscal second quarter 2025 earnings release, where the company posted a strong quarter after a weaker first quarter for 2025. Myriad Genetics, Inc. (NASDAQ:MYGN) posted revenue of $213.10 million, reflecting around 1% year-over-year growth and ahead of expectations by $10.8 million. The EPS of $0.05 also exceeded expectations by $0.06.

Brennan noted that this was mainly due to a solid performance in Hereditary Cancer Testing and GeneSight. However, he highlighted that the Prenatal segment remains weak, and the outlook for the second half of 2025 hints at a possible decline in year-over-year growth. The company also faces challenges from the loss of a GeneSight contract and issues with electronic medical records affecting volumes, thereby resulting in a cautious rating from the analyst.

Myriad Genetics, Inc. (NASDAQ:MYGN) is a genetic testing and precision medicine company that develops genetic tests to help assess disease risk and guide treatment decisions.

While we acknowledge the potential of MYGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.